Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
- Conditions
- Coronavirus Disease 2019
- Interventions
- Drug: Pentarlandir™ UPPTADrug: Placebo
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- SyneuRx International (Taiwan) Corp
- Target Recruit Count
- 90
- Registration Number
- NCT04911777
- Locations
- 🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Cactus Clinical Research, Inc., Gilbert, Arizona, United States
🇺🇸Synergy Healthcare, Bradenton, Florida, United States
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- SyneuRx International (Taiwan) Corp
- Target Recruit Count
- 287
- Registration Number
- NCT03094429
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena, California, United States
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- SyneuRx International (Taiwan) Corp
- Target Recruit Count
- 280
- Registration Number
- NCT02261519
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena, California, United States
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- SyneuRx International (Taiwan) Corp
- Target Recruit Count
- 60
- Registration Number
- NCT01908192
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸CiTrials, Riverside, California, United States
🇺🇸Renew Behavioral Health, Inc., Long Beach, California, United States